New lung cancer medicines before surgery for unresectable stage III
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have unresectable stage III non-small cell lung cancer
- Your cancer has no known sensitizing EGFR mutation and no ALK fusion
- You are 18–74 years old and can take oral study medicines and attend follow-ups
- Your health is fairly strong (ECOG performance status 0–1) and you have at least 12 weeks of expected survival
- Your blood counts and organ tests (liver, kidneys) are within required limits
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests an experimental drug called IBI363 given before surgery for early-stage non-small cell lung cancer. The goal is to see if it can help shrink the tumor and improve the chances of successful surgery.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
Hear when a new Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.